(Reuters) -Johnson & Johnson said on Thursday its cancer therapy combination met the main goal in a late-stage study testing it as a treatment for patients with a type of lung cancer.
The drugmaker said an interim analysis of data from the study showed a trend “favoring” the combination of its antibody treatment Rybrevant and experimental drug lazertinib, when compared to AstraZeneca’s cancer drug osimertinib or Tagrisso.
J&J said it plans to submit data for an upcoming scientific conference, including additional details on certain secondary goals from the study.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila and Shinjini Ganguli)
